{
  "label": "Sample, fictional data",
  "notice": "Halden Therapeutics AG is a fictional organization. The evidence is written for this sample. The shape of the export is not fictional.",
  "record": "halden-therapeutics-ag",
  "entity": {
    "name": "Halden Therapeutics AG",
    "anchor": "haldentx.com",
    "kind": "Company",
    "opened": "2025-10-09"
  },
  "as_of": "2026-03-12",
  "reader": "Research analyst, public-sources clearance",
  "values": [
    {
      "property": "lead_program",
      "label": "Lead program",
      "status": "cited",
      "value": "HLD-204",
      "excerpt": "Following the January reprioritisation, HLD-204 is our lead candidate and our principal development priority.",
      "source": "Corporate presentation, February 2026",
      "locator": "slide 4",
      "observed": "2026-03-11",
      "entered": "2026-03-11",
      "competing": [
        {
          "value": "HLD-118",
          "source": "haldentx.com/pipeline, page not revised since August 2025",
          "observed": "2026-03-11",
          "reason": "A dated presentation outranks an unrevised web page."
        }
      ],
      "reader_clearance": "open; no source licence restricts this value"
    },
    {
      "property": "mechanism",
      "label": "Mechanism",
      "status": "blocked",
      "value": null,
      "note": "A characterisation of the target exists in a journal this reader is not cleared to read. The article has not been retrieved and nothing from it is asserted here. The public pipeline page calls HLD-204 a pan-RAS inhibitor, which the record holds as a competing claim rather than an answer, because the page names no assay.",
      "source": "Journal of Medicinal Chemistry 69(4), subscription",
      "locator": "doi:10.1021/acs.jmedchem.5c02211",
      "reader_clearance": "Licensed source, not permitted for reader clearance public-sources.",
      "attempted": "2026-03-12"
    },
    {
      "property": "development_phase",
      "label": "Development phase",
      "status": "cited",
      "value": "Phase 2",
      "excerpt": "This open-label Phase 2 study of HLD-204 in previously treated metastatic pancreatic adenocarcinoma is currently recruiting.",
      "source": "ClinicalTrials.gov NCT06712233, record version 9",
      "locator": "clinicaltrials.gov/study/NCT06712233",
      "observed": "2026-03-11",
      "entered": "2026-03-11",
      "competing": [
        {
          "value": "Phase 1/2",
          "source": "Company press release, 14 January 2026",
          "observed": "2026-03-11",
          "reason": "The registry record outranks a press release about it."
        }
      ],
      "reader_clearance": "open; no source licence restricts this value"
    },
    {
      "property": "headquarters",
      "label": "Headquarters",
      "status": "cited",
      "value": "Basel, Switzerland",
      "excerpt": "Halden Therapeutics AG maintains its registered office at Aeschenvorstadt 24, 4051 Basel.",
      "source": "Commercial Register of Basel-Stadt, extract CHE-417.882.106",
      "locator": "page 1",
      "observed": "2026-03-12",
      "entered": "2026-03-12",
      "competing": [
        {
          "value": "Cambridge, Massachusetts",
          "source": "Press release boilerplate, 3 February 2025",
          "observed": "2025-10-09",
          "reason": "A register extract outranks press-release boilerplate."
        },
        {
          "value": "Zug, Switzerland",
          "source": "Delegate listing, BIO-Europe 2025",
          "observed": "2025-11-22",
          "reason": "A delegate listing is not an assertion about the office."
        }
      ],
      "reader_clearance": "open; no source licence restricts this value"
    },
    {
      "property": "phase_2_readout_date",
      "label": "Phase 2 readout date",
      "status": "not_found",
      "value": null,
      "note": "No source we hold states a readout date. The registry's estimated primary completion is a different quantity and is not reported as one.",
      "searched": [
        {
          "what": "ClinicalTrials.gov NCT06712233, record version 9",
          "date": "2026-03-11",
          "result": "estimated primary completion only"
        },
        {
          "what": "Corporate presentation, February 2026",
          "date": "2026-03-11",
          "result": "the phrase in due course"
        },
        {
          "what": "Investor call transcript, 26 February 2026",
          "date": "2026-03-12",
          "result": "question asked, not answered"
        },
        {
          "what": "Two conference abstracts, AACR 2026",
          "date": "2026-03-13",
          "result": "Phase 1 data only"
        }
      ],
      "reader_clearance": "open"
    }
  ]
}